Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, on Tuesday announced the successful completion of patient enrollment in its Phase 1b/2a CENDIFOX trial.
This investigator-initiated trial is evaluating the safety and efficacy of Lisata's iRGD cyclic peptide product candidate, Certepetide, in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com